Precision Quantomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Precision Quantomics is a private, early-stage diagnostics and tools company founded in 2019 and headquartered in Cambridge, Massachusetts. It leverages advanced mass spectrometry-based proteomics to create quantitative assay kits and services that help predict drug-induced liver injury (DILI), drug metabolism, and transport, aligning with regulatory shifts toward non-animal testing. The company operates a hybrid business model, selling proprietary assay kits (e.g., MSQ-DILI, MSQ-CYP) while offering contract services and consultancy, primarily serving pharmaceutical and biotech clients. It is currently in a pre-revenue or early-revenue stage, focusing on platform validation and market adoption.

Diagnostics

Technology Platform

Mass spectrometry-based quantitative proteomics platform specializing in targeted quantification of transmembrane proteins (drug-metabolizing enzymes, transporters, receptors) at femtomole to attomole levels. Platform includes standardized assay kits (MSQ series) for ADMET prediction and characterization of advanced in vitro models.

Opportunities

The FDA's drive to reduce animal testing creates a large, immediate market for tools that qualify New Approach Methodologies (NAMs).

Precision Quantomics' quantitative proteomics assays are essential for validating that organ-on-a-chip models accurately reflect human biology, positioning the company as a critical enabler of this regulatory transition.

Additionally, the persistent need to de-risk drug candidates earlier in development provides a steady demand for its ADMET prediction kits and services.

Risk Factors

Market adoption is contingent on the pace of regulatory acceptance and industry uptake of NAMs, which may be slower than expected.

The company faces competition from larger, established reagent suppliers and CROs that could develop similar offerings.

As a small, private company, it also carries execution risks in scaling operations, sales, and manufacturing to meet potential demand.

Competitive Landscape

Precision Quantomics competes in the proteomics reagents and drug discovery services market against large life science tools companies (e.g., Thermo Fisher, Agilent) and specialized CROs offering ADMET testing. Its differentiation lies in its specific focus on quantitative, mass spectrometry-based kits for transmembrane proteins and its explicit alignment with the NAM qualification niche. Competition is intense, but the regulatory shift may create a new segment where specialized expertise provides an advantage.

More companies in Diagnostics & Precision Medicine →More companies in United States →